Literature DB >> 23188472

Rhabdomyolysis in a multiple myeloma patient secondary to concurrent treatment with lenalidomide and pravastatin and to lenalidomide alone.

Jaime L Shahan1, Lori D Panu, Gerhard C Hildebrandt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23188472     DOI： 10.1007/s12185-012-1226-3

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  9 in total

1.  Thalidomide in combination with dexamethasone-induced rhabdomyolysis in a patient with refractory myeloma.

Authors:  Can Boga; Hakan Ozdogu; Mahmut Yeral; Ebru Kizilkilic; Lulufer Tamer
Journal:  J Support Oncol       Date:  2007-06

2.  Lenalidomide in combination with dexamethasone induced rhabdomyolysis in a multiple myeloma patient treated with pravastatin.

Authors:  Chisako Urata; Mariko Yoshimura; Hidekazu Itamura; Takashi Hisatomi; Yasushi Kubota; Noriyasu Fukushima; Eisaburo Sueoka; Shinya Kimura
Journal:  Int J Hematol       Date:  2011-08-03       Impact factor: 2.490

Review 3.  Novel lenalidomide-based combinations for treatment of multiple myeloma.

Authors:  Mauro Cives; Valeria Simone; Oronzo Brunetti; Vito Longo; Franco Silvestris
Journal:  Crit Rev Oncol Hematol       Date:  2012-07-17       Impact factor: 6.312

4.  A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL.

Authors:  J R Brown; J Abramson; E Hochberg; E Mikler; V Dalton; L Werner; H Reynolds; C Thompson; S M McDonough; Y Kuang; J Ritz; D Neuberg; A S Freedman
Journal:  Leukemia       Date:  2010-09-16       Impact factor: 11.528

Review 5.  New immunomodulatory drugs in myeloma.

Authors:  Martha Q Lacy
Journal:  Curr Hematol Malig Rep       Date:  2011-06       Impact factor: 3.952

6.  Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis.

Authors:  A Matsuoka; A Tochigi; M Kishimoto; T Nakahara; T Kondo; T Tsujioka; T Tasaka; Y Tohyama; K Tohyama
Journal:  Leukemia       Date:  2010-02-04       Impact factor: 11.528

7.  Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.

Authors:  Nianhang Chen; Henry Lau; Linghui Kong; Gondi Kumar; Jerome B Zeldis; Robert Knight; Oscar L Laskin
Journal:  J Clin Pharmacol       Date:  2007-10-22       Impact factor: 3.126

8.  Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma.

Authors:  Ellen van der Spek; Andries C Bloem; Henk M Lokhorst; Berris van Kessel; Lijnie Bogers-Boer; Niels W C J van de Donk
Journal:  Leuk Res       Date:  2008-07-14       Impact factor: 3.156

9.  Single-dose pharmacokinetics of lenalidomide in healthy volunteers: dose proportionality, food effect, and racial sensitivity.

Authors:  N Chen; C Kasserra; J Reyes; L Liu; H Lau
Journal:  Cancer Chemother Pharmacol       Date:  2012-09-06       Impact factor: 3.333
  9 in total
  2 in total

Review 1.  Clinical use of statins in hematopoietic stem cell transplantation: Old drugs and new horizons.

Authors:  Mehdi Mohammadi; Mohammad Vaezi; Bahador Mirrahimi; Molouk Hadjibabaie
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2016-01-01

2.  Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report.

Authors:  Yuta Adachi; Naohiro Yanagimura; Chiaki Suzuki; Sakiko Ootani; Azusa Tanimoto; Akihiro Nishiyama; Kaname Yamashita; Koushiro Ohtsubo; Shinji Takeuchi; Seiji Yano
Journal:  BMC Cancer       Date:  2020-02-24       Impact factor: 4.430
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.